Sangamo Therapeutics Inc
(LTS:0R1D)
$
1.9196
-0.0403 (-2.06%)
Market Cap: 417.29 Mil
Enterprise Value: 405.82 Mil
PE Ratio: 0
PB Ratio: 10.37
GF Score: 34/100 Sangamo Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020 / 08:00PM GMT
Release Date Price:
$11.74
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to introduce Sandy Macrae, the CEO of Sangamo. Thanks for joining us today, Sandy.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
It's my pleasure.
Questions & Answers
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat conversation. So maybe to kick it off, if you can give an introduction to Sangamo for people who might not be familiar with the story.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
So Sangamo is a fascinating company. It's -- we're known as a zinc finger company, but we truly have evolved to become a genomic medicine company. And in this time of COVID and all the challenges that we are facing, the health of Sangamo is great. We
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot